Matthew Harrison -- Morgan Stanley -- Analyst
Great. Good afternoon. Thanks for taking the question. A question on Galapagos, and I guess there are two parts here.
First part is, you know, you've got these upcoming Toledo readouts. Merdad, maybe you could just comment on what you're potentially looking to see from those readouts, given that the duration of those trials is fairly short. So maybe what you would view as sort of a positive outcome. And then I guess second question is a more sort of broader strategic question here.
But if you don't see something that's positive out of those, you know, how do you think about the longer-term relationship there? And given that you're the largest shareholder, you know, what might you consider in terms of that relationship?
Vraag tijdens Gilead persco met de analisten. Verder was er welgeteld 1 zin over Toledo readout van Gilead zelf.
Antwoord Gilead:
Merdad Parsey -- Chief Medical Officer
Yes, sure. It's a great question. And I think you -- Matthew, you mentioned, I think, look, where we are now with the Toledo programs is looking for evidence of tolerability and proof-of-concept, proof of principle for that pathway in multiple indications. And I would describe these early small studies as a place to demonstrate that and look to see where the biggest impact could be.
I think it's an early part of the longer journey, ranging from -- you know, is there a particular indication that we want to pursue further to confirm and expand on the signal to -- you know, do we have the right molecule for that. So I think we view these, together with Galapagos, I believe, we view these as sort of very early in the story of the Toledo program. So we'll be looking to see what those data look like in the near term. Dan, do you want add?
Dus vraag is hoeveel we van resultaat dat zo prematuur is mogen verwachten.
maar dan komt O’Day aan het woord: